Hikma, Vectura in dispute with FDA over generic Advair

LONDON (Reuters) - Hikma and its partner Vectura are in dispute with the Food and Drug Administration over their plans to launch a generic copy of GlaxoSmithKline's popular lung drug Advair in the U.S. market, delaying any eventual approval.